Comparative Pharmacology
Head-to-head clinical analysis: METOZOLV ODT versus PROMETHAZINE PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METOZOLV ODT versus PROMETHAZINE PLAIN.
METOZOLV ODT vs PROMETHAZINE PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective 5-HT3 receptor antagonist; blocks serotonin action at vagal nerve terminals and in the chemoreceptor trigger zone, inhibiting emetic reflex.
Promethazine is a phenothiazine derivative that acts primarily as a histamine H1 receptor antagonist, blocking the effects of histamine at H1 receptors. It also has anticholinergic, antiemetic, sedative, and local anesthetic properties. Its antiemetic effect is mediated through blockade of dopamine D2 receptors in the chemoreceptor trigger zone.
2.5 mg to 5 mg orally once daily, as disintegrating tablet; may increase to 10 mg if needed
25-50 mg orally, intramuscularly, or rectally every 4-6 hours as needed; maximum 100 mg per dose
None Documented
None Documented
~1.5–2 hours in normal renal function; prolonged to 10–20 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 10-19 hours (average 12-15 hours). Clinical context: Requires repeated dosing for sustained effect; dosing interval typically every 6-12 hours.
Renal: ~70% as unchanged drug; biliary/fecal: ~30% as metabolites and unchanged drug.
Primarily renal excretion of metabolites; less than 1% excreted unchanged. Biliary/fecal elimination accounts for approximately 25-30%.
Category C
Category A/B
Antiemetic
Antihistamine / Antiemetic